/
MNKD
$4.14-$0.00 (-0.12%)live
Held · Bookmarked
0 · 0
portfolios · users
Avg position size
—
of holders' portfolios
13F filers
1
institution
Market cap
$1.3B
309M shares
52-week range
$2.23 – $6.51
45% from low
Sector
PHARMACEUTICAL PREPARATIONS
Exchange
NASDAQ
CS
Borrow rate
0.39%
Easy to borrow
Price (6 mo)
Loading chart…
Change$-1.32
Valuation
Financials
Loading chart…
Click rows below (any statement) to add/remove series. Selection stays as you switch tabs.
| 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | |
|---|---|---|---|---|---|---|---|---|
| Revenue | $27.9M | $63.0M | $65.1M | $75.4M | $99.8M | $199.0M | $285.5M | $349.0M |
| Cost of revenue | $20.5M | $28.0M | $24.6M | $38.9M | $57.5M | $62.8M | $76.6M | $61.2M |
| Gross profit | $7.4M | $35.1M | $40.5M | $36.6M | $42.3M | $136.2M | $208.9M | $287.8M |
| Gross margin | 26.5% | 55.6% | 62.2% | 48.5% | 42.4% | 68.5% | 73.2% | 82.5% |
| R&D | $8.7M | $6.9M | $6.2M | $12.3M | $19.7M | $31.3M | $45.9M | $66.3M |
| Operating income | −$76.6M | −$44.6M | −$47.9M | −$47.0M | −$64.1M | $8.7M | $72.6M | $38.8M |
| EBITDA | −$75.6M | −$38.8M | −$44.7M | −$61.1M | −$56.3M | $15.1M | $77.5M | $27.5M |
| Net income | −$87.0M | −$51.9M | −$57.2M | −$80.9M | −$87.4M | −$11.9M | $27.6M | $5.9M |
| Net margin | -312.2% | -82.3% | -87.9% | -107.3% | -87.6% | -6.0% | 9.7% | 1.7% |
| EPS (diluted) | -0.60 | -0.31 | -0.26 | -0.37 | -0.44 | -0.04 | 0.10 | 0.02 |
Annual figures · source: Financial Modeling Prep
Analyst estimates (consensus)
| Year | Est. revenue | Est. EPS | EPS range | # Analysts |
|---|---|---|---|---|
| 2026 | $462M | $-0.02 | $-0.05–$0.02 | 5 |
| 2027 | $521M | $0.14 | $0.05–$0.31 | 5 |
| 2028 | $536M | $0.16 | $-0.24–$0.38 | 8 |
| 2029 | $611M | $0.31 | $0.29–$0.33 | 6 |
Forward consensus · source: Financial Modeling Prep
Peer comparison
Mannkind Corporation
MannKind Corp is a biopharmaceutical company focused on the development and commercialization of patient-centric therapies that address serious unmet medical needs for those living with cardiometabolic and orphan lung diseases. The Company is currently commercializing three products: Afrezza (insulin human) Inhalation Powder, an ultra rapid-acting inhaled insulin indicated to improve glycemic control in adults with diabetes; Furoscix (furosemide injection), to treat fluid buildup in patients with chronic heart failure or chronic kidney disease; and the V-Go wearable insulin delivery device, which provides continuous subcutaneous infusion of insulin in adults that require insulin.
www.mannkindcorp.com- Employees
- 592
- IPO / List date
- Jul 28, 2004
- HQ
- DANBURY, CT
Held by traders on TradeandTell
No one on the platform currently holds MNKD.
Super investors & insiders
Institutions holding (13F)
| Institution | Shares | Reported |
|---|---|---|
| Renaissance Technologiesas of 2026-03-31 | 1,868,442 | $4.6M |
Insider activity (SEC Form 4)
Stock splits
| Execution date | Ratio |
|---|---|
| 2017-03-03 | 1-for-5reverse |
Recent trades on TradeandTell
No one on the platform has traded MNKD yet.
